Form 4: Organogenesis Holdings Inc. Executive Receives Stock Options and Restricted Stock Units

Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., was granted stock options and restricted stock units (RSUs) on February 19, 2025.

Summary

• Robert Cavorsi, Vice President of Strategy at Organogenesis Holdings Inc., received a grant of 63,830 stock options and 61,705 restricted stock units (RSUs) on February 19, 2025.
• The stock options have an exercise price of $3.53 and become exercisable in equal annual installments over four years, starting February 15, 2025, and expire on February 19, 2035.
• The RSUs vest in equal annual installments over four years, beginning February 15, 2025, with each RSU representing the right to receive one share of Organogenesis Class A common stock upon vesting.
• Following the reported transactions, Cavorsi directly owns 63,830 derivative securities and 190,463 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity compensation is a standard practice and signals confidence in the executive's ability to contribute to the company's success. There are no immediate negative implications.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Future Outlook

The vesting schedule of the RSUs and the exercisability of the stock options suggest a long-term commitment from the executive to the company's success.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract, retain, and incentivize key personnel. The specific terms of the grant (vesting schedule, exercise price) are typical for executive compensation packages.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation plans to align executive incentives with shareholder value.

Stakeholder Impact

• Shareholders may view the equity compensation positively as it aligns management's interests with long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

Organogenesis Holdings Inc., Robert Cavorsi, stock options, RSUs, equity compensation, Form 4, ORGO